-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.78 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.150B Est

Benzinga·10/28/2026 07:58:30
Listen to the news
GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.78 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.150 billion estimate.